|
News Shire’s VENVANSE® (lisdexamfetamine dimesylate) Marketing Application accepted for review in Europe
Shire plc, the global specialty biopharmaceutical company, announced the acceptance for review of their once-daily ADHD medicinal product VENVANSE® (lisdexamfetamine dimesylate) by the Medicines Healthcare products Regulatory Agency (MHRA), UK. |
|
News EU study shows once-daily lisdexamfetamine dimesylate (LDX) effective for symptom control in children and adolescents with ADHD
Shire plc the global specialty biopharmaceutical company, presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder (ADHD). |